INOVIO, a biotech company specializing in DNA medicines for HPV-related diseases and cancer, will announce its Q3 2026 financial results after market close on November 10, 2026. The company will hold a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the webcast on INOVIO's website, with the replay available for 90 days. This event offers insight into INOVIO's financial health and ongoing developments in its innovative DNA medicine technology.
INOVIO is set to release its Q3 2026 financial results on November 10, 2026, a key event for investors following its recent price surge. On Pluang, INO trades at USD 1.86 with a remarkable 1-day gain of 208.76% as of Nov 03, 2026 04:11 WIB, showing strong market interest ahead of the report.
INOVIO, a biotech company specializing in DNA medicines for HPV-related diseases, cancer, and infectious diseases, announced it will present at two upcoming scientific conferences in November 2026. The presentations will cover next-generation DNA med...
INOVIO received accelerated FDA approval for VOCERYQ, a DNA-based immunotherapy that reduces surgery frequency in adults with recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV-6 and HPV-11. VOCERYQ, the first FDA-approved DNA m...
